- Home
- APLT vs GEG Comparison
APLT vs GEG Comparison
Compare APLT & GEG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- GEG
- Stock Information
- Founded
- APLT 2016
- GEG 1994
- Country
- APLT United States
- GEG United States
- Employees
- APLT N/A
- GEG N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- GEG Computer Software: Prepackaged Software
- Sector
- APLT Health Care
- GEG Technology
- Exchange
- APLT Nasdaq
- GEG Nasdaq
- Market Cap
- APLT 69.0M
- GEG 63.0M
- IPO Year
- APLT 2019
- GEG N/A
- Fundamental
- Price
- APLT $0.51
- GEG $2.47
- Analyst Decision
- APLT Buy
- GEG
- Analyst Count
- APLT 6
- GEG 0
- Target Price
- APLT $6.10
- GEG N/A
- AVG Volume (30 Days)
- APLT 893.4K
- GEG 9.4K
- Earning Date
- APLT 08-13-2025
- GEG 09-02-2025
- Dividend Yield
- APLT N/A
- GEG N/A
- EPS Growth
- APLT N/A
- GEG N/A
- EPS
- APLT N/A
- GEG N/A
- Revenue
- APLT $121,000.00
- GEG $19,626,000.00
- Revenue This Year
- APLT $415.60
- GEG N/A
- Revenue Next Year
- APLT $1,323.96
- GEG N/A
- P/E Ratio
- APLT N/A
- GEG N/A
- Revenue Growth
- APLT N/A
- GEG 64.34
- 52 Week Low
- APLT $0.30
- GEG $1.70
- 52 Week High
- APLT $10.62
- GEG $2.54
- Technical
- Relative Strength Index (RSI)
- APLT 61.88
- GEG 73.25
- Support Level
- APLT $0.47
- GEG $2.06
- Resistance Level
- APLT $0.53
- GEG $2.54
- Average True Range (ATR)
- APLT 0.03
- GEG 0.10
- MACD
- APLT 0.00
- GEG 0.04
- Stochastic Oscillator
- APLT 83.33
- GEG 86.00
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About GEG Great Elm Group Inc.
Great Elm Group Inc operates as an alternative asset manager focused on growing a scalable and diversified portfolio of long-duration and permanent capital vehicles across credit, real estate, specialty finance, and other alternative strategies. Along with its subsidiaries, it manages Great Elm Capital Corp, a publicly traded business development company, and Monomoy Properties REIT, LLC, an industrial-focused real estate investment trust, in addition to other investments.